First Phase III Trial to Combine a Microbiome Pill with Cancer Immunotherapy Enrolls Over 700 Kidney Cancer Patients
The SWOG S2419 BioFront study is the first large-scale randomized trial testing whether a daily oral bacterial supplement can boost immunotherapy outcomes in advanced kidney cancer.
Overview
The SWOG Cancer Research Network has launched the S2419 BioFront study, the first Phase III randomized clinical trial anywhere to test a gut microbiome intervention as part of a cancer therapy regimen. The trial will enroll more than 700 patients with advanced clear cell renal cell carcinoma and randomize them to receive standard immunotherapy with or without a daily oral capsule of CBM588, a live bacterial product containing Clostridium butyricum, according to an announcement from the University Hospitals Seidman Cancer Center.
The study is chaired by Pedro Barata, a medical oncologist and Miggo Family Chair in Cancer Research at UH Seidman Cancer Center, and is funded by the National Cancer Institute.
What We Know
CBM588 is a nonpathogenic bacterium that produces butyrate, a short-chain fatty acid known to support gut lining integrity and modulate immune function. The capsule formulation requires no refrigeration or special handling, a practical advantage for deployment across clinical sites. All participants in the BioFront trial will receive a physician-selected, standard-of-care immunotherapy regimen, and will then be randomized to receive either CBM588 or a placebo, as described in the trial announcement.
The trial’s primary endpoint is progression-free survival, with secondary endpoints including objective response rate, overall survival, quality-of-life measures focused on gastrointestinal symptoms, and assessment of dietary fiber intake associations. A safety run-in phase will monitor the first 50 randomized patients for three months before broader enrollment continues.
Earlier Phase Results
The BioFront study builds on two earlier Phase I randomized trials that produced striking, if preliminary, signals.
In the first trial, 30 patients with metastatic renal cell carcinoma were randomized 2:1 to receive nivolumab plus ipilimumab with or without CBM588. Patients in the CBM588 arm achieved a median progression-free survival of 12.7 months compared to 2.5 months in the control arm, with a hazard ratio of 0.15 (P = 0.001). The objective response rate was 58 percent with CBM588 versus 20 percent without. No significant difference in grade 3-4 adverse events was observed between the two groups.
A second Phase I trial tested CBM588 alongside cabozantinib and nivolumab in another cohort of 30 patients. While the study’s primary microbiome endpoint — an increase in Bifidobacterium abundance — was not met, the clinical results were notable: the objective response rate reached 74 percent with CBM588 compared to 20 percent without (P = 0.01). Six-month landmark progression-free survival rates were 84 percent versus 60 percent. The prevalence of grade 3 or 4 adverse events was similar across both arms at 40 percent each.
What We Don’t Know
The mechanism by which CBM588 appears to enhance immunotherapy remains incompletely understood. The second Phase I trial found that treatment enriched unclassified Ruminococcaceae genera rather than the expected Bifidobacterium, and metabolomic analysis revealed enhanced vitamin K2 biosynthesis pathways, as reported in the trial publication. Whether these microbiome shifts are causally linked to the improved clinical outcomes or are merely correlated has not been established.
Both prior trials enrolled only 30 patients each, a sample size too small to draw definitive conclusions. The BioFront trial’s enrollment of over 700 patients is designed to provide the statistical power needed to determine whether the early signals hold up at scale.
It is also unclear whether the benefits of CBM588 extend beyond clear cell renal cell carcinoma to other tumor types where checkpoint inhibitors are used, or whether baseline microbiome composition affects individual response to the bacterial supplement.
Analysis
The BioFront study represents a milestone for the microbiome therapeutics field, which has faced a pattern of promising preclinical results followed by disappointing clinical translations. If the Phase III data confirm even a fraction of the effect sizes seen in the earlier trials, it could reshape how oncologists think about the relationship between gut health and cancer treatment.
The trial also arrives at a moment of broader momentum in microbiome research. As previously reported, recent studies have identified gut bacterial metabolites that double lung cancer immunotherapy response in mice, and a Cambridge-led consortium has mapped previously hidden bacterial groups linked to overall health. The BioFront trial is the first to take these converging lines of evidence into a large-scale, registration-quality clinical setting for cancer treatment.
Barata’s trial development received partial support from a 2023 Coltman Fellowship from The Hope Foundation for Cancer Research, according to the study announcement. SWOG, founded in 1956, is a publicly funded cancer research network — positioning the study to generate data that could influence both clinical practice guidelines and regulatory pathways.